Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study
Authors:
- Alison C. JohnsonAJAlison C. Johnson
- Margarida MatiasMMMargarida Matias
- Helen BoyleHBHelen Boyle
- Bernard EscudierBEBernard Escudier
- Alicia MolinierAMAlicia Molinier
- Brigitte LaguerreBLBrigitte Laguerre
- Carole HelisseyCHCarole Helissey
- Pierre-Emmanuel BrachetPBPierre-Emmanuel Brachet
- Loic MoureyLMLoic Mourey
- Elodie CoquanECElodie Coquan
- Florence JolyFJFlorence Joly
Open Access
- 22 May 2017
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 17 (1) , 355
Abstract
Axitinib is used after failure of first line treatment for metastatic renal cell carcinoma (mRCC). A known side effect is the increase of haemoglobin level (HbL) during treatment with a suspected correlation with better outcome. Our objective was to examine whether HbL increase during the first three months of axitinib treatment is associated with better prognosis. Retrospective multicentre analysis including patients with mRCC treated with axitinib for at least three months from 2012 to 2014. Progression-free survival (PFS) was analysed by a Cox model according to gender, International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic score, high blood pressure (hBP), and maximum increase in HbL within the first three months of treatment. Ninety-eight patients were analysed (71% men; median age at treatment initiation: 62 years; IMDC: 24%, 50%, and 26% in the favourable, intermediate, and poor-risk group, respectively). Patients received axitinib for a median of 8 months. During the first three months, the median increase of HbL was +2.3 g/dL (−1.1; 7.2). Fifty-six (57%) patients developed hBP. In multivariate analysis, after adjustment for performance status (P < 0.0001) and gender (P = 0.0041), the combination of HbL increase ≥2.3 g/dL and any grade hBP was significantly associated with longer PFS (HR = 0.40, 95%CI [0.24; 0.68]). Early HbL increase during axitinib treatment combined with hBP is an independent predictive factor of PFS. These results require validation in a prospective setting.Keywords
This publication has 17 references indexed in Scilit:
- Symptomatic Secondary Polycythemia Induced by Anti-VEGF Therapy for the Treatment of Metastatic Renal Cell Carcinoma: A Case Series and ReviewClinical Genitourinary Cancer, 2015
- The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based studyThe Lancet Oncology, 2015
- Effects of Vascular Endothelial Growth Factor Signaling Inhibition on Human ErythropoiesisThe Oncologist, 2013
- Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinomaBritish Journal of Cancer, 2013
- Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid TumorsClinical Cancer Research, 2011
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter StudyJournal of Clinical Oncology, 2009
- Axitinib Induces Paradoxical Erythropoietin Synthesis in Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2009
- Secondary Erythrocytosis Produced by the Tyrosine Kinase Inhibitors Sunitinib and SorafenibJournal of Clinical Oncology, 2008
- Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panelBlood, 2007
- VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesisNature Medicine, 2006